Abstract
Biosimilars are biological products similar to, but not the same as, the innovator products. Both the European Medicines Agency and the Food and Drug Administration have released detailed guidance on the development of biosimilars. This guidance requires the pivotal phase 3 clinical study to have an equivalence design, which means that the study objective is to demonstrate that one treatment is neither “worse than” nor “better than” the other by some “clinically unimportant” amount. The most critical and controversial step in designing such a study is the choice of equivalence margin, as this determines the conclusion of the study. In this paper, we outline the methodology for determining an equivalence margin and, through case studies on biosimilar trastuzumab (HERCEPTIN) and biosimilar bevacizumab (AVASTIN), explain the challenges of applying this in practice and why the synthesis method should be given greater consideration by regulatory authorities and biosimilar developers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev. 1. July 1, 2015.
FDA. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. April 2015.
Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36–39.
Schumi J, Wittes J. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106–117.
Rothmann M, Li N, Chen G, et al. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. 2003; 22:239–264.
Rothmann MD, Tsou HH. On non-inferiority analysis based on delta-method confidence intervals. J Biopharm Stat 2003;13:565–583.
FDA Draft Guidance for Industry, Non-Inferiority Clinical Trials, March 2010.
Combest AJ, Wang S, Healey BT, Reitsma DJ. Alternative statistical strategies for biosimilar drug development. GaBI J. 2014: 3:13–20.
Yining Y, Bin Y. Demonstrating biosimilarity via equivalence in clinical trials. Stat Biopharm Res. 2012;4:264–272.
CHMP. Guideline on the choice of non-inferiority margin, EMEA/CPMP/EWP/2158/99, July 2005.
Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open 2016;2:e000154. doi:https://doi.org/10.1136/rmdopen-2015000154.
Herceptin®: European public assessment report—scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000278/WC500049816.pdf
Herceptin®: European public assessment report—product information 11/07/2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf
FDA label for Herceptin®. revised October 2010.
Herceptin®: FDA statistical review. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm091381.pdf.
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol. 2005;23(19):4265–4274.
Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 or metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
Wangge G, Roes KC, de Boer A, Hoes AW, Knol MJ. The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. CMAJ. 2013;185(3):222–227.
Amgevita European Public Assessment Report (EPAR). EMA/106922/2017. January 26, 2017.
ABP501: Statistical review and evaluation. September 7, 2016.
Carroll KJ. Statistical issues and controversies in active-controlled, “noninferiority” trials. Stat Biopharm Res. 2013;5(3):229–238.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–1234.
Niho SI, Kunitoh H, Nokihara H, et al.; JO19907 Study Group. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76:362–367.
Johnson DH, Fehrenbacher L, Novotny WF, et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22: 2184–91.
FDA. Briefing document. Arthritis Advisory Committee meeting. BLA 761024, ABP 501, a proposed biosimilar to Humira (adalimumab). July 12, 2016.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clark, T., Jo, S.J. & Phillips, A. Sample Size for Biosimilar Trials: In Defense of Synthesis. Ther Innov Regul Sci 52, 300–305 (2018). https://doi.org/10.1177/2168479017729189
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479017729189